RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R‐MAXICHOP/HD‐ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS. (June 2017) - Klener, P.